Effects of Psilocybin in Anorexia Nervosa

This open-label pilot investigates safety and efficacy of psilocybin administered in a supportive setting with close follow-up in adults with chronic anorexia nervosa; primary aims are safety, reduction in anxiety and depression, and improved quality of life.

Participants may receive up to four moderate-to-high oral psilocybin sessions (first session 20 mg, subsequent sessions may increase by 5 mg to a maximum of 30 mg); outcomes include clinical measures of eating-disorder pathophysiology, mood, and safety assessments.